Premium
Long‐Term Results of Valve Replacement with the CarboMedics Prosthetic Heart Valve
Author(s) -
Onoda Koji,
Suzuki Tomoaki,
Kanemitsu Naoki,
Yuasa Uhito,
Takao Motoshi,
Shimono Takatsugu,
Tanaka Kuniyoshi,
Shimpo Hideto,
Yada Isao
Publication year - 2002
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1046/j.1525-1594.2002.06978.x
Subject(s) - medicine , surgery , thrombosis , incidence (geometry) , aortic valve , endocarditis , mitral valve , cardiology , prosthesis , optics , physics
This study examined the long‐term results of the CarboMedics prosthetic heart valve. Between July 1990 and May 2000, 256 CarboMedics valve prostheses (120 single aortic, 62 single mitral, and 34 double aortic/mitral) were implanted into 216 patients (mean age 57.8 years). The mean follow‐up was 57.7 ± 36 months (maximum 133 months) with a total of 1,038.4 patient years. Patient survival, including operative deaths, was 85.1% at 10 years. Linearized rates for various complications were thromboembolism 0.39% per patient year, bleeding events 0.39% per patient year; prosthetic valve endocarditis 0.29% per patient year, nonstructural dysfunction 0.87% per patient year, and reoperation 0.39% per patient year. There were no valve thrombosis or structural valve failures in this series. The probabilities of freedom from thromboembolism and reoperation at 10 years were 96.3% and 93.1%, respectively. In conclusion, the CarboMedics valve can be used satisfactorily with a low incidence of thromboembolism and valve thrombosis.